Journal
CURRENT HYPERTENSION REPORTS
Volume 12, Issue 6, Pages 456-464Publisher
SPRINGER
DOI: 10.1007/s11906-010-0151-1
Keywords
Genetic testing; Paraganglioma; Pheochromocytoma; Multiple endocrine neoplasia type 2; von Hippel-Lindau disease; Neurofibromatosis type 1; Succinate dehydrogenase complex genes; Immunohistochemistry; Catecholamines
Categories
Funding
- Intramural NIH HHS [Z01 HD008735-07] Funding Source: Medline
Ask authors/readers for more resources
Pheochromocytomas (PHEOs) and paragangliomas (PGLs) are rare, catecholamine-producing tumors that are usually sporadic. However, about 30% of these tumors have been identified as being of inherited origin. To date, nine genes have been confirmed as participating in PHEO or PGL tumorigenesis. Germline mutations were found in 100% of syndromic cases and in about 90% of patients with positive familial history. In nonsyndromic patients with apparently sporadic tumors, genetic mutations have been found in up to 27%, and genetic testing is now recommended for all patients with PHEOs and PGLs. Patients with syndromic lesions, a positive family history, or both should be tested for the appertaining gene. Recent discoveries have shown that the order of tested genes in nonsyndromic, nonfamilial cases can be based on histologic evaluation, location, and the biochemical phenotype of PHEOs and PGLs-the rule of three. Identification of a gene mutation may lead to early diagnosis and treatment, regular surveillance, and a better prognosis for patients and their relatives.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available